Volume 13, Number 6—June 2007
Letter
Multidrug-Resistant Acinetobacter baumannii
Vladimir Krcmery*
and Erich Kalavsky†
and Erich Kalavsky†
Table
Risk factors and outcome for 27 neutropenic cancer patients with bacteremia due to multidrug-resistant (MDR) or drug-susceptible Acinetobacter baumannii infection
| Characteristic | All patients, no. (%) (N = 27) | Patients with drug-susceptible A. baumannii, no. (%)* (n = 12, 44%) | Patients with MDR A. baumannii, no. (%)* (n = 15, 56%) |
|---|---|---|---|
| Risk for bacteremia | |||
| Central venous catheter | 19 (70.4) | 9 (75.0) | 10 (66.7) |
| Acute leukemia | 11 (40.7) | 6 (50.0) | 5 (33.3) |
| Previous prophylaxis with quinolones | 14 (51.9) | 8 (66.7) | 6 (40.0) |
| Previous therapeutic treatment with cephalosporins | 15 (55.6) | 8 (66.7) | 7 (46.7) |
| Previous therapeutic treatment with carbapenems | 8 (29.6) | 4 (33.3) | 4 (26.7) |
| Outcome | |||
| Septic shock | 4 (14.8) | 2 (16.7) | 2 (13.3) |
| Death | 2 (7.4) | 1 (8.3) | 1 (6.7) |
*Insignificant difference between patients with drug-susceptible infection and those with MDR infection (p<0.05 by univariate analysis).
Page created: July 05, 2010
Page updated: July 05, 2010
Page reviewed: July 05, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.